Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUCCESSOR-2: mezigdomide + carfilzomib + dexamethasone versus carfilzomib + dexamethasone in relapsed or refractory multiple myeloma
MOH_2023-10-31_013024Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mezigdomide, carfilzomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Started Jan 2024; status: active, not recruiting.
02
Drugs
mezigdomidecarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-10-31_013024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-31_013024.